by Dr. Julie Nonnekens, Erasmus MC
This talk describes the extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. In vivo imaging was performed on the MILabs VECTorCT imaging platform.
Took place: November, 2020